SynopsisGranisetron is an antagonist of the serotonin (5-HT) receptor subtype 5-HT3 (Ki = 3.9 nM) with antiemetic activity. The global Granisetron HCl Reagent market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a .....
SynopsisGranisetron is a serotonin 5-HT3 receptor antagonist,used to treat chemotherapy-induced nausea and vomiting. The global Granisetron HCl API market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % d.....
SynopsisIsavuconazonium is a water-soluble prodrug form of the azole antifungal isavuconazole (ISA). The global Isavuconazonium Sulfate Reagent market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % durin.....
SynopsisIsavuconazonium is a water-soluble prodrug form of the azole antifungal isavuconazole (ISA). The global Isavuconazonium Sulfate API market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during th.....
SynopsisMelengestrol acetate is an antineoplastic agent. The global Melengestrol Acetate Reagent market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030. North Am.....
SynopsisMelengestrol acetate is a steroidal progestin and antineoplastic agent. The global Melengestrol Acetate API market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2.....
SynopsisMigalastat is a competititve inhibitor of α-galactosidase. The global Migalasta Reagent market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030. North Ame.....
SynopsisMigalastat is a pharmacological chaperone that reversibly binds to the active site of the alpha-galactosidase A (alpha-Gal A) protein, which is deficient in Fabry disease. The global Migalastat API market was valued at US$ million in 2023 and is anticipa.....
SynopsisMirabegron is a β3-AR (β3 adrenergic receptor) agonist of bladder muscles The global Mirabegron Reagent market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030......
SynopsisMirabegron is a drug for the treatment of overactive bladder. The global Mirabegron API market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030. North Ame.....








